|
1
|
Wakimoto H, Tanaka S, Curry WT, Loebel F,
Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, et al:
Targetable signaling pathway mutations are associated with
malignant phenotype in IDH-mutant gliomas. Clin Cancer Res.
20:2898–2909. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yiin JJ, Hu B, Schornack PA, Sengar RS,
Liu KW, Feng H, Lieberman FS, Chiou SH, Sarkaria JN, Wiener EC, et
al: ZD6474, a multitargeted inhibitor for receptor tyrosine
kinases, suppresses growth of gliomas expressing an epidermal
growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer
Ther. 9:929–941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yue X, Lan F, Hu M, Pan Q, Wang Q and Wang
J: Downregulation of serum microRNA-205 as a potential diagnostic
and prognostic biomarker for human glioma. J Neurosurg. Jul
31–2015.(Epub ahead of print). PubMed/NCBI
|
|
4
|
Yeom SY, Nam DH and Park C: RRAD promotes
EGFR-mediated STAT3 activation and induces temozolomide resistance
of malignant glioblastoma. Mol Cancer Ther. 13:3049–3061. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Loftus JC, Dhruv H, Tuncali S, Kloss J,
Yang Z, Schumacher CA, Cao B, Williams BO, Eschbacher JM, Ross JT,
et al: TROY (TNFRSF19) promotes glioblastoma survival signaling and
therapeutic resistance. Mol Cancer Res. 11:865–874. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oliva CR, Nozell SE, Diers A, McClugage SG
III, Sarkaria JN, Markert JM, Darley-Usmar VM, Bailey SM, Gillespie
GY, Landar A, et al: Acquisition of temozolomide chemoresistance in
gliomas leads to remodeling of mitochondrial electron transport
chain. J Biol Chem. 285:39759–39767. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ramirez YP, Mladek AC, Phillips RM,
Gynther M, Rautio J, Ross AH, Wheelhouse RT and Sakaria JN:
Evaluation of novel imidazotetrazine analogues designed to overcome
temozolomide resistance and glioblastoma regrowth. Mol Cancer Ther.
14:111–119. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park I, Mukherjee J, Ito M, Chaumeil MM,
Jalbert LE, Gaensler K, Ronen SM, Nelson SJ and Pieper RO: Changes
in pyruvate metabolism detected by magnetic resonance imaging are
linked to DNA damage and serve as a sensor of temozolomide response
in glioblastoma cells. Cancer Res. 74:7115–7124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smalley S, Chalmers AJ and Morley SJ: mTOR
inhibition and levels of the DNA repair protein MGMT in T98G
glioblastoma cells. Mol Cancer. 13:1442014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gupta SK, Mladek AC, Carlson BL,
Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J and
Sarkaria JN: Discordant in vitro and in vivo chemopotentiating
effects of the PARP inhibitor veliparib in temozolomide-sensitive
versus-resistant glioblastoma multiforme xenografts. Clin Cancer
Res. 20:3730–3741. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cen L, Carlson BL, Pokorny JL, Mladek AC,
Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W,
et al: Efficacy of protracted temozolomide dosing is limited in
MGMT unmethylated GBM xenograft models. Neuro Oncol. 15:735–746.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Melguizo C, Prados J, González B, Ortiz R,
Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R,
et al: MGMT promoter methylation status and MGMT and CD133
immunohistochemical expression as prognostic markers in
glioblastoma patients treated with temozolomide plus radiotherapy.
J Transl Med. 10:2502012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Etcheverry A, Aubry M, Idbaih A, Vauleon
E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon
L, Quillien V, et al: DGKI methylation status modulates the
prognostic value of MGMT in glioblastoma patients treated with
combined radio-chemotherapy with temozolomide. PLoS One.
9:e1044552014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nguyen SA, Stechishin OD, Luchman HA, Lun
XQ, Senger DL, Robbins SM, Cairncross JG and Weiss S: Novel MSH6
mutations in treatment-naïve glioblastoma and anaplastic
oligodendroglioma contribute to temozolomide resistance
independently of MGMT promoter methylation. Clin Cancer Res.
20:4894–4903. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee KE: Immunohistochemical assessment of
O(6)-methylguanine-DNA methyltransferase (MGMT) and its
relationship with p53 expression in endometrial cancers. J Cancer
Prev. 18:351–354. 2013. View Article : Google Scholar
|
|
16
|
Lavon I, Fuchs D, Zrihan D, Efroni G,
Zelikovitch B, Fellig Y and Siegal T: Novel mechanism whereby
nuclear factor kappaB mediates DNA damage repair through regulation
of O(6)-methylguanine-DNA-methyltransferase. Cancer Res.
67:8952–8959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Persano L, Pistollato F, Rampazzo E, Della
Puppa A, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R and
Basso G: BMP2 sensitizes glioblastoma stem-like cells to
Temozolomide by affecting HIF-1α stability and MGMT expression.
Cell Death Dis. 3:e4122012. View Article : Google Scholar
|
|
18
|
Janssens S, Tinel A, Lippens S and Tschopp
J: PIDD mediates NF-kappaB activation in response to DNA damage.
Cell. 123:1079–1092. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rawat N, Alhamdani A, McAdam E, Cronin J,
Eltahir Z, Lewis P, Griffiths P, Baxter JN and Jenkins GJ: Curcumin
abrogates bile-induced NF-κB activity and DNA damage in vitro and
suppresses NF-κB activity whilst promoting apoptosis in vivo,
suggesting chemopreventative potential in Barrett's oesophagus.
Clin Transl Oncol. 14:302–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dong QG, Sclabas GM, Fujioka S, Schmidt C,
Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, et
al: The function of multiple IkappaB: NF-kappaB complexes in the
resistance of cancer cells to Taxol-induced apoptosis. Oncogene.
21:6510–6519. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li F and Sethi G: Targeting transcription
factor NF-kappaB to overcome chemoresistance and radioresistance in
cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
|
|
22
|
Vyas AR, Hahm ER, Arlotti JA, Watkins S,
Stolz DB, Desai D, Amin S and Singh SV: Chemoprevention of prostate
cancer by d,l-sulforaphane is augmented by pharmacological
inhibition of autophagy. Cancer Res. 73:5985–5995. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cornblatt BS, Ye L, Dinkova-Kostova AT,
Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E,
Argani P, et al: Preclinical and clinical evaluation of
sulforaphane for chemoprevention in the breast. Carcinogenesis.
28:1485–1490. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lenzi M, Fimognari C and Hrelia P:
Sulforaphane as a promising molecule for fighting cancer. Cancer
Treat Res. 159:207–223. 2014. View Article : Google Scholar
|
|
25
|
Pledgie-Tracy A, Sobolewski MD and
Davidson NE: Sulforaphane induces cell type-specific apoptosis in
human breast cancer cell lines. Mol Cancer Ther. 6:1013–1021. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin LC, Yeh CT, Kuo CC, Lee CM, Yen GC,
Wang LS, Wu CH, Yang WC and Wu AT: Sulforaphane potentiates the
efficacy of imatinib against chronic leukemia cancer stem cells
through enhanced abrogation of Wnt/β-catenin function. J Agric Food
Chem. 60:7031–7039. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chaudhuri D, Orsulic S and Ashok BT:
Antiproliferative activity of sulforaphane in Akt-overexpressing
ovarian cancer cells. Mol Cancer Ther. 6:334–345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lan F, Yu H, Hu M, Xia T and Yue X:
miR-144-3p exerts anti-tumor effects in glioblastoma by targeting
c-Met. J Neurochem. 135:274–286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamini B, Yu X, Dolan ME, Wu MH, Darga TE,
Kufe DW and Weichselbaum RR: Inhibition of nuclear factor-kappaB
activity by temozolomide involves O6-methylguanine induced
inhibition of p65 DNA binding. Cancer Res. 67:6889–6898. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Caporali S, Levati L, Graziani G, Muzi A,
Atzori MG, Bonmassar E, Palmieri G, Ascierto PA and D‘Atri S: NF-κB
is activated in response to temozolomide in an AKT-dependent manner
and confers protection against the growth suppressive effect of the
drug. J Transl Med. 10:2522012. View Article : Google Scholar
|
|
31
|
Lan F, Pan Q, Yu H and Yue X: Sulforaphane
enhances temozolomide-induced apoptosis because of down-regulation
of miR-21 via Wnt/β-catenin signaling in glioblastoma. J Neurochem.
134:811–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li R, Tang D, Zhang J, Wu J, Wang L and
Dong J: The temozolomide derivative 2T-P400 inhibits glioma growth
via administration route of intravenous injection. J Neurooncol.
116:25–30. 2014. View Article : Google Scholar
|
|
33
|
Grossman SA, Ye X, Piantadosi S, Desideri
S, Nabors LB, Rosenfeld M and Fisher J; NABTT CNS Consortium.
Survival of patients with newly diagnosed glioblastoma treated with
radiation and temozolomide in research studies in the United
States. Clin Cancer Res. 16:2443–2449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grossman R, Rudek MA, Brastianos H, Zadnik
P, Brem H, Tyler B and Blakeley JO: The impact of bevacizumab on
temozolomide concentrations in intracranial U87 gliomas. Cancer
Chemother Pharmacol. 70:129–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun S, Lee D, Ho AS, Pu JK, Zhang XQ, Lee
NP, Day PJ, Lui WM, Fung CF and Leung GK: Inhibition of prolyl
4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide
resistance in malignant glioma via the endoplasmic reticulum stress
response (ERSR) pathways. Neuro Oncol. 15:562–577. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weller M, Gorlia T, Cairncross JG, van den
Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, MacDonald DR,
Forsyth P, et al: Prolonged survival with valproic acid use in the
EORTC/NCIC temozolomide trial for glioblastoma. Neurology.
77:1156–1164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu X, Han EK, Anderson M, Shi Y,
Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J, et
al: Acquired resistance to combination treatment with temozolomide
and ABT-888 is mediated by both base excision repair and homologous
recombination DNA repair pathways. Mol Cancer Res. 7:1686–1692.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ciechomska IA, Gabrusiewicz K,
Szczepankiewicz AA and Kaminska B: Endoplasmic reticulum stress
triggers autophagy in malignant glioma cells undergoing
cyclosporine a-induced cell death. Oncogene. 32:1518–1529. 2013.
View Article : Google Scholar
|
|
39
|
Tergaonkar V, Pando M, Vafa O, Wahl G and
Verma I: p53 stabilization is decreased upon NFkappaB activation: A
role for NFkappaB in acquisition of resistance to chemotherapy.
Cancer Cell. 1:493–503. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brassesco MS, Roberto GM, Morales AG,
Oliveira JC, Delsin LE, Pezuk JA, Valera ET, Carlotti CG Jr, Rego
EM, de Oliveira HF, et al: Inhibition of NF-κB by
dehydroxymethylepoxyquinomicin suppresses invasion and
synergistically potentiates temozolomide and γ-radiation
cytotoxicity in glioblastoma cells. Chemother Res Pract.
2013:5930202013.
|
|
41
|
Sai K, Li WY, Chen YS, Wang J, Guan S,
Yang QY, Guo CC, Mou YG, Li WP and Chen ZP: Triptolide
synergistically enhances temozolomide-induced apoptosis and
potentiates inhibition of NF-κB signaling in glioma initiating
cells. Am J Chin Med. 42:485–503. 2014. View Article : Google Scholar
|
|
42
|
Wagner L, Marschall V, Karl S, Cristofanon
S, Zobel K, Deshayes K, Vucic D, Debatin KM and Fulda S: Smac
mimetic sensitizes glioblastoma cells to Temozolomide-induced
apoptosis in a RIP1- and NF-κB-dependent manner. Oncogene.
32:988–997. 2013. View Article : Google Scholar
|
|
43
|
Turrini E, Ferruzzi L and Fimognari C:
Natural compounds to overcome cancer chemoresistance: Toxicological
and clinical issues. Expert Opin Drug Metab Toxicol. 10:1677–1690.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Asakage M, Tsuno NH, Kitayama J, Tsuchiya
T, Yoneyama S, Yamada J, Okaji Y, Kaisaki S, Osada T, Takahashi K,
et al: Sulforaphane induces inhibition of human umbilical vein
endothelial cells proliferation by apoptosis. Angiogenesis.
9:83–91. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim HN, Kim DH, Kim EH, Lee MH, Kundu JK,
Na HK, Cha YN and Surh YJ: Sulforaphane inhibits phorbol
ester-stimulated IKK-NF-κB signaling and COX-2 expression in human
mammary epithelial cells by targeting NF-κB activating kinase and
ERK. Cancer Lett. 351:41–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Singh SV, Warin R, Xiao D, Powolny AA,
Stan SD, Arlotti JA, Zeng Y, Hahm ER, Marynowski SW, Bommareddy A,
et al: Sulforaphane inhibits prostate carcinogenesis and pulmonary
metastasis in TRAMP mice in association with increased cytotoxicity
of natural killer cells. Cancer Res. 69:2117–2125. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Forster T, Rausch V, Zhang Y, Isayev O,
Heilmann K, Schoensiegel F, Liu L, Nessling M, Richter K, Labsch S,
et al: Sulforaphane counteracts aggressiveness of pancreatic cancer
driven by dysregulated Cx43-mediated gap junctional intercellular
communication. Oncotarget. 5:1621–1634. 2014. View Article : Google Scholar : PubMed/NCBI
|
